Equity Profile

BBIO

BRIDGEBIO PHARMA INC

Health CareBiotechnology$13.2B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

BridgeBio Pharma Inc (BBIO) is a biotechnology company focused on developing therapies for genetic diseases. With a market cap of $13 billion, it plays a significant role in the healthcare sector, particularly in addressing unmet medical needs through innovative treatments.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs relative to revenue.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and successfully commercialize its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BBIO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.09%

Avg Stock Reaction

+0.50%

Last Quarter Recap

In Q1-2026, BridgeBio reported an EPS of -$0.84, missing estimates by 19.32%. The stock reacted negatively, dropping 0.94% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to improving operational efficiency.
Plans to enhance partnerships with research institutions.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about BridgeBio's upcoming earnings, especially given the company's focus on innovative therapies. However, past performance has shown mixed results, leading to uncertainty.

Bull Case

If BridgeBio can demonstrate significant progress in its clinical trials and show improved financial metrics, it could lead to a strong positive reaction from the market.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its therapies, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What progress has been made in clinical trials for key therapies?

This will be crucial for understanding the company's growth potential and future revenue streams.

How does management plan to address recent EPS misses?

Investor confidence may hinge on management's strategy to improve financial performance moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for BridgeBio's therapies to gain traction despite recent EPS misses, as the company has a strong pipeline.

Supporting Evidence

The options market is pricing in a 1.75% move, indicating lower expectations than historical averages.

Insider selling could suggest a lack of confidence in short-term performance, which may not reflect the long-term potential of the pipeline.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether BridgeBio can turn around its financial performance and successfully advance its drug pipeline.

Bull Confirmed If

Demonstrating a significant reduction in EPS losses or a clear path to profitability would confirm the bull case.

Bear Confirmed If

Continued EPS losses without a clear turnaround plan would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±1.75%

Historical Avg

±2.2%

Pricing cheap

The options market is pricing in a modest move around the earnings report, suggesting that investors are anticipating some volatility but not drastic changes.

Options are pricing ±1.8% while BBIO has averaged ±2.2% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

41.9%

Calls (144K)P/C Ratio: 0.38Puts (7K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$6.0M

80,000 sh

1 insider

Net

$6.0M

Net selling

Most Active Insiders· 8 open-market trades

Chief Executive OfficerKumar Neil
$6.0M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BridgeBio beats expectations, history suggests the stock could rise by about 1.48% on the next trading day, confirming a positive outlook.

In-Line / Cautious

If the results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with historical data suggesting an average drop of around 1.48%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·0 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key therapies.
2Any commentary on operational efficiency improvements.
3Management's strategy to address recent EPS misses.
4Insights into potential partnerships or collaborations.
5Future guidance on revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs relative to revenue.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and successfully commercialize its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BBIO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.09%

Avg Stock Reaction

+0.50%

Last Quarter Recap

In Q1-2026, BridgeBio reported an EPS of -$0.84, missing estimates by 19.32%. The stock reacted negatively, dropping 0.94% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to improving operational efficiency.
Plans to enhance partnerships with research institutions.

Expectations

Wall Street Expectations

Bull Case

If BridgeBio can demonstrate significant progress in its clinical trials and show improved financial metrics, it could lead to a strong positive reaction from the market.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its therapies, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What progress has been made in clinical trials for key therapies?

This will be crucial for understanding the company's growth potential and future revenue streams.

How does management plan to address recent EPS misses?

Investor confidence may hinge on management's strategy to improve financial performance moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for BridgeBio's therapies to gain traction despite recent EPS misses, as the company has a strong pipeline.

Supporting Evidence

The options market is pricing in a 1.75% move, indicating lower expectations than historical averages.

Insider selling could suggest a lack of confidence in short-term performance, which may not reflect the long-term potential of the pipeline.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether BridgeBio can turn around its financial performance and successfully advance its drug pipeline.

Bull Confirmed If

Demonstrating a significant reduction in EPS losses or a clear path to profitability would confirm the bull case.

Bear Confirmed If

Continued EPS losses without a clear turnaround plan would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±1.75%

Historical Avg

±2.2%

Pricing cheap

The options market is pricing in a modest move around the earnings report, suggesting that investors are anticipating some volatility but not drastic changes.

Options are pricing ±1.8% while BBIO has averaged ±2.2% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

41.9%

Calls (144K)P/C Ratio: 0.38Puts (7K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$6.0M

80,000 sh

1 insider

Net

$6.0M

Net selling

Most Active Insiders· 8 open-market trades

Chief Executive OfficerKumar Neil
$6.0M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BridgeBio beats expectations, history suggests the stock could rise by about 1.48% on the next trading day, confirming a positive outlook.

In-Line / Cautious

If the results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with historical data suggesting an average drop of around 1.48%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·0 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key therapies.
2Any commentary on operational efficiency improvements.
3Management's strategy to address recent EPS misses.
4Insights into potential partnerships or collaborations.
5Future guidance on revenue expectations.